PLEASE NOTE: THESE SLIDES MAY NOT DISPLAY PROPERLY ONLINE, BUT THEY ARE READABLE IF DOWNLOADED. October 28, 2018 This one-day conference explored the current pharmaceutical pricing landscape by bringing together leaders from the pharmaceutical industry, policymakers, legal practitioners, and scholars to engage in novel, interdisciplinary discussions to better understand current challenges and articulate best practices to address these issues. Participants assessed the current challenges presented in drug pricing policy, from development to delivery, in both the United States and international context. We also explored and articulated best practices to expand access to medicines and worked toward developing a plan for disseminating these practices more widely.

1. Sara Gerke
Research Fellow for Precision Medicine
PMAIL (Project on Precision Medicine, Artificial
Intelligence, and the Law)
Petrie-Flom Center for Health Law Policy,
Biotechnology, and Bioethics
sgerke@law.harvard.edu
AI in Drug
Discovery and
Clinical Trials

2. Agenda
▣ What is AI?
▣ Uses of AI in
o Drug Discovery
o Clinical Trials
▣ Challenges
2

3. What is AI?
3
1. Thinking Humanly
2. Acting Humanly
3. Thinking Rationally
4. Acting Rationally
Russell and Norvig, Artificial Intelligence: A Modern Approach,
3rd Edition

4. AI in Drug Discovery
4
• Enabling Precision Medicine
• Acceleration of the Drug Discovery Process
• Discovery of New Drug Targets &
Alternative Drug Indications
• Cost Reduction

5. • Higher Efficiency
(e.g., helping with
recruiting)
• Higher Safety
(e.g., screening
subjects for
adverse reactions)
• Expediting
Clinical Trials
• Cost Reduction
5
AI in Clinical Trials

6. 6
Challenges
• Safety and
Effectiveness
• Reliable Data
Sets
• Bias
• Data Sharing
• Data Diversity
• Transparency
• Oversight
• Liability
• Data Privacy
Etc.

7. Thanks!
@gerke_sara
sgerke@law.harvard.edu